Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry

Antibody Engineering Platform

The Antibody Platform Technology

The development of innovative therapeutics is becoming an increasingly important research strategy for Queen Mary University of London (QMUL). The newly established antibody platform enables the development of high-profile therapeutic strategies with broad applications that will boost cutting-edge discovery programmes across QMUL and Barts Health. The Platform at the William Harvey Research Institute (WHRI) already supports several areas of translational research with the aim of developing antibody immunotherapeutic/antibody drug conjugate. Phage display human antibody libraries are commonly employed to develop human monoclonal antibodies for treatment. We have already built several human antibody libraries from healthy volunteers, infected individuals, and patients with various diseases as a source of raising human monoclonal antibodies for clinical application. We are working across all the disease areas at the WHRI, Barts Cancer Institute (BCI) and the Blizard Institute. Our current activities include programmes in basic and translational research in inflammation, infectious diseases, autoimmunity and cancer.

If you have a project that you think we could help with, please get in touch and we design the experimental approach with you.

Background

Monoclonal antibodies represent an almost limitless source of therapeutic and diagnostic reagents and have become a major part of treatment in various diseases. The importance of antibody in treatment of disease has recently become more evident in the fight against the COVID pandemic. Phage display technology produce fully human antibodies to rapidly translate discovered antibodies to clinic and to overcome the unwanted human response to the classical mouse monoclonal antibodies. Phage display libraries encompass a mixture of filamentous bacteriophage each displaying a different antibody fragment and thereby possess different specificity.

Contacts

Prof Ahuva Nissim
Head of Antibody Engineering Platform
Biochemical Pharmacology
William Harvey Research Institute
Email: a.nissim@qmul.ac.uk
Phone: 020 7882 3990

Dr Faheem Shaik
Antibody Engineering Platform Manager
Biochemical Pharmacology
William Harvey Research Institute
Email: f.shaik@qmul.ac.uk 

Dr Elisa Corsiero
Centre for Experimental Medicine & Rheumatology
William Harvey Research Institute
Email: e.corsiero@qmul.ac.uk
Phone: 020 7882 8193

Location
William Harvey Research Institute
1st-floor Charterhouse Square
London, UK
EC1M 6BQ

Back to top